The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Monsalves, Eric ^a,b   Juraschka, Kyle ^b   Tateno, Toru ^c   Agnihotri, Sameer ^a   Asa, Sylvia L ^a   Ezzat, Shereen ^a,c   Zadeh, Gelareh ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

MTOR; MTOR inhibitor; Pituitary adenoma; RAD001; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; HUMAN; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; RADIATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ADENOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; PITUITARY NEOPLASMS;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84905987431     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0188     Document Type: Review

References (96)

1. Abbass SA, Asa SL & Ezzat S 1997 Altered expression of fibroblast growth factor receptors in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 82 1160-1166. (doi:10.1210/jcem.82.4.3896)
2. Advani SH 2010 Targeting mTOR pathway: a new concept in cancer therapy. Indian Journal of Medical and Paediatric Oncology 31 132-136. (doi:10.4103/0971-5851.76197)
3. Altmeyer A, Josset E, Denis JM, Gueulette J, Slabbert J, Mutter D, Noel G & Bischoff P 2012 The mTOR inhibitor RAD001 augments radiationinduced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. International Journal of Oncology 41 1381-1386. (doi:10.3892/ijo. 2012.1583)
4. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Skele KL, Hoffman JP & Testa JR 2002 Frequent activation of AKT2 kinase in human pancreatic carcinomas. Journal of Cellular Biochemistry 87 470-476. (doi:10.1002/jcb.10287)
5. Asa SL & Ezzat S 1998 The cytogenesis and pathogenesis of pituitary adenomas. Endocrine Reviews 19 798-827. (Pubitemid 128506522)
6. Asa SL & Ezzat S 2009 The pathogenesis of pituitary tumors. Annual Review of Pathology 4 97-126. (doi:10.1146/annurev.pathol.4.110807.092259)
7. Bader AG, Kang S & Vogt PK 2006 Cancer-specific mutations in PIK3CA are oncogenic in vivo. PNAS 103 1475-1479. (doi:10.1073/pnas.0510857103)
8. Banerjee S, Saxena N, Sengupta K & Banerjee SK 2003 17alpha-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. Biochemical and Biophysical Research Communications 300 209-215. (doi:10.1016/S0006-291X(02)02830-9)
9. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA & Thomas G 2005 The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 747-759. (doi:10.1016/j.cell.2004.12.040)
10. Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S & Uttley D 1993 The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clinical Endocrinology 38 571-578. (doi:10.1111/j.1365-2265.1993.tb02137.x)
11. Brognard J, Clark AS, Ni Y & Dennis PA 2001 Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research 61 3986-3997. (Pubitemid 32720961)
12. Burris HA III 2013 Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemotherapy and Pharmacology 71 829-842.
13. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK & Theodoropoulou M 2010 The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Research 70 666-674. (doi:10.1158/0008-5472.CAN-09-2951)
14. Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP & Seshadri MS 2010 The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13 337-344. (doi:10.1007/s11102-010-0242-7)
15. Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW& Baker SJ 2011 Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19 305-316. (doi:10.1016/j.ccr.2011.01.039)
16. Clark AS, West K, Streicher S & Dennis PA 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapeutics 1 707-717.
17. Cooper O, Vlotides G, Fukuoka H, Greene MI & Melmed S 2011 Expression and function of ErbB receptors and ligands in the pituitary. Endocrine-Related Cancer 18 R197-R211. (doi:10.1530/ERC-11-0066)
18. Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J et al. 2013 Inhibition of PI3K/AKT/mTOR pathway enhances temozo-lomide- induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 154 1247-1259. (doi:10.1210/en.2012- 1908)
19. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y & Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 231-241. (doi:10.1016/S0092-8674(00)80405-5)
20. Douros J & Suffness M 1981 New natural products under development at the National Cancer Institute. Recent Results in Cancer Research 76 153-175.
21. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M et al. 2009 Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocrine-Related Cancer 16 1329-1338. (doi:10.1677/ERC-09-0101)
22. Ezzat S 2001 The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathology 11 356-370. (doi:10.1111/j.1750-3639. 2001.tb00405.x)
23. Ezzat S, Zheng L, Zhu XF, Wu GE & Asa SL 2002 Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation 109 69-78. (doi:10.1172/JCI14036)
24. Ezzat S, Zheng L & Asa SL 2004 Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/ N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Molecular Endocrinology 18 2543-2552. (doi:10.1210/me.2004- 0182)
25. Ezzat S, Zheng L, Winer D & Asa SL 2006 Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Molecular Endocrinology 20 2965-2975. (doi:10.1210/me.2006-0223)
26. Faivre S, Kroemer G & Raymond E 2006 Current development of mTOR inhibitors as anticancer agents. Nature Reviews. Drug Discovery 5 671-688. (doi:10.1038/nrd2062)
27. Fernandez M, Sanchez-Franco F, Palacios N, Sanchez I, Villuendas G & Cacicedo L 2003 Involvement of vasoactive intestinal peptide on insulin-like growth factor I-induced proliferation of rat pituitary lactotropes in primary culture: evidence for an autocrine and/or paracrine regulatory system. Neuroendocrinology 77 341-352. (doi:10.1159/000070900)
28. Fernandez M, Sanchez-Franco F, Palacios N, Sanchez I, Fernandez C & Cacicedo L 2004 IGF-I inhibits apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway in pituitary cells. Journal of Molecular Endocrinology 33 155-163. (doi:10.1677/jme.0.0330155)
29. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S & Melmed S 2011 HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Molecular Endocrinology 25 92-103. (doi:10.1210/me.2010-0353)
30. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M & Shimon I 2009 Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocrine-Related Cancer 16 1017-1027. (doi:10.1677/ERC-08-0269)
31. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD & Muller WJ 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. PNAS 89 10578-10582. (doi:10.1073/pnas.89.22. 10578)
32. Guzzo MF, Carvalho LR & Bronstein MD 2014 Apoptosis: its role in pituitary development and neoplastic pituitary tissue. Pituitary 17 157-162. (doi:10.1007/s11102-013-0481-5)
33. Hahn CA, Zhou SM, Raynor R, Tisch A, Light K, Shafman T, Wong T, Kirkpatrick J, Turkington T, Hollis D et al. 2009 Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. International Journal of Radiation Oncology, Biology, Physics 73 1082-1087. (doi:10.1016/j.ijrobp.2008.05.061)
34. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR et al. 2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. Journal of Cell Biology 166 213-223. (doi:10.1083/jcb.200403069)
35. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN & Farrell WE 1999 Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clinical Cancer Research 5 2133-2139. (Pubitemid 29399269)
36. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB & Thomas G 1997 Rapamycin suppresses 5 0 TOPmRNA translation through inhibition of p70s6k. EMBO Journal 16 3693-3704. (doi:10.1093/emboj/16.12.3693)
37. Johnson MD, O'Connell MJ, Pilcher W & Reeder JE 2010 Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. Journal of Neurosurgery 112 934-939. (doi:10.3171/2009.7.JNS09726)
38. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J & Raverot G 2012 New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15 37-43. (doi:10.1007/s11102- 011-0341-0)
39. Kandel ES & Hay N 1999 The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Experimental Cell Research 253 210-229. (doi:10.1006/excr.1999.4690)
40. Kawashima K, Yamakawa K & Arita J 2000 Involvement of phosphoinositide-3-kinase and p70 S6 kinase in regulation of proliferation of rat lactotrophs in culture. Endocrine 13 385-392. (doi:10.1385/ENDO:13:3:385)
41. Kenerson H, Dundon TA & Yeung RS 2005 Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatric Research 57 67-75. (doi:10.1203/01.PDR.0000147727.78571.07)
42. Kowarik M, Onofri C, Colaco T, Stalla GK & Renner U 2010 Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells. Experimental and Clinical Endocrinology & Diabetes 118 113-120. (doi:10.1055/s-0029-1202832)
43. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P & Dammann RH 2010 Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. Journal of Investigative Dermatology 130 620-622. (doi:10.1038/jid.2009.226)
44. Lamberts SW, de Herder WW & Hofland LJ 2002 Somatostatin analogs in the diagnosis and treatment of cancer. Trends in Endocrinology and Metabolism 13 451-457. (doi:10.1016/S1043-2760(02)00667-7)
45. Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC & Pellegata NS 2011 Levels of p27 sensitize to dual PI3K/mTOR inhibition. Molecular Cancer Therapeutics 10 1450-1459. (doi:10.1158/1535-7163.MCT-11-0188)
46. LeRiche VK, Asa SL & Ezzat S 1996 Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. Journal of Clinical Endocrinology and Metabolism 81 656-662. (doi:10.1210/jcem.81.2.8636285)
47. Leslie NR, Biondi RM & Alessi DR 2001 Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chemical Reviews 101 2365-2380. (doi:10.1021/cr000091i)
48. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M & Lu Y 2009 Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocrine-Related Cancer 16 301-310. (doi:10.1677/ERC-08-0167)
49. Lu C, Willingham MC, Furuya F & Cheng SY 2008 Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149 3339-3345. (doi:10.1210/en.2007-1696)
50. Ma S, Liu X, Yao Y, Cai F, Dai C, Bao X, Feng M, Wei J, Zhang B, Li G et al. 2011 Effect of temozolomide on cell viability in gonadotroph adenoma cell lines. Oncology Reports 26 543-550. (doi:10.3892/or.2011.1317)
51. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K et al. 2008 Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics 7 1851-1863. (doi:10.1158/1535-7163.MCT- 08-0017)
52. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR et al. 2004 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10 594-601. (doi:10.1038/nm1052)
53. Manning BD, Tee AR, Logsdon MN, Blenis J & Cantley LC 2002 Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Molecular Cell 10 151-162. (doi:10.1016/S1097-2765(02)00568-3)
54. Mauceri HJ, Sutton HG, Darga TE, Kocherginsky M, Kochanski J, Weichselbaum RR & Vokes EE 2012 Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncology Reports 27 1625-1629. (doi:10.3892/or.2012.1666)
55. Medema RH, Kops GJ, Bos JL & Burgering BM 2000 AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404 782-787. (doi:10.1038/35008115)
56. Mete O & Asa SL 2012 Clinicopathological correlations in pituitary adenomas. Brain Pathology 22 443-453. (doi:10.1111/j.1750-3639.2012.00599.x)
57. Mhawech-Fauceglia P, Wang D, Kim G, Sharifian M, Chen X, Liu Q, Lin YG, Liu S & Pejovic T 2014 Expression of DNA repair proteins in endometrial cancer predicts disease outcome. Gynecologic Oncology 132 593-598. (doi:10.1016/j.ygyno.2014.02.002)
58. Muller WJ, Sinn E, Pattengale PK, Wallace R & Leder P 1988 Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54 105-115. (doi:10.1016/0092-8674(88)90184-5)
59. Murat CB, Braga PB, Fortes MA, Bronstein MD, Correa-Giannella ML & Giorgi RR 2012 Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. Brazilian Journal of Medical and Biological Research 45 851-855. (doi:10.1590/S0100-879X2012007500115)
60. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T & Sugihara K 2009 Relation between outcomes and localisation of p-mTOR expression in gastric cancer. British Journal of Cancer 100 782-788. (doi:10.1038/sj.bjc.6604915)
61. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M et al. 2005 Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-Related Cancer 12 423-433. (doi:10.1677/erc.1.00949)
62. Nam SY, Lee HS, Jung GA, Choi J, Cho SJ, Kim MK, Kim WH & Lee BL 2003 Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 111 1105-1113. (doi:10.1111/j.1600-0463.2003. apm1111205.x)
63. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B & Segelov E 2004 PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23 617-628. (doi:10.1038/sj.onc.1207059)
64. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH & Lee EJ 2009 Predicting recurrence of nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 94 4406-4413. (doi:10.1210/jc.2009-0471)
65. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM et al. 2008 PIK3CA cooperates with other phosphatidylinositol 3 0 kinase pathway mutations to effect oncogenic transformation. Cancer Research 68 8127-8136. (doi:10.1158/0008-5472.CAN-08- 0755)
66. Ooi GT, Tawadros N & Escalona RM 2004 Pituitary cell lines and their endocrine applications. Molecular and Cellular Endocrinology 228 1-21. (doi:10.1016/j.mce.2004.07.018)
67. Oostra A, van Furth W & Georgalas C 2012 Extended endoscopic endonasal skull base surgery: from the sella to the anterior and posterior cranial fossa. ANZ Journal of Surgery 82 122-130. (doi:10.1111/j.1445-2197.2011. 05971.x)
68. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (doi:10.1158/0008-5472.CAN-05-2925)
69. Perez-Tenorio G & Stal O 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. British Journal of Cancer 86 540-545. (doi:10.1038/sj.bjc.6600126)
70. Revillion F, Bonneterre J & Peyrat JP 1998 ERBB2 oncogene in human breast cancer and its clinical significance. European Journal of Cancer 34 791-808. (doi:10.1016/S0959-8049(97)10157-5)
71. Riemenschneider MJ, Betensky RA, Pasedag SM & Louis DN 2006 AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Research 66 5618-5623. (doi:10.1158/0008-5472.CAN-06-0364)
72. Romano D, Pertuit M, Rasolonjanahary R, Barnier JV, Magalon K, Enjalbert A & Gerard C 2006 Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells. Endocrinology 147 6036-6045. (doi:10.1210/en.2006- 0325)
73. Rose A, Froment P, Perrot V, Quon MJ, LeRoith D & Dupont J 2004 The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase Calpha-mediated negative regulation of Akt. Journal of Biological Chemistry 279 52500-52516. (doi:10.1074/jbc.M404571200)
74. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT & Smyrk TC 2002 AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23 201-205. (doi:10.1093/carcin/ 23.1.201)
75. Saeger W 2004 Proliferation markers and cell cycle inhibitors in pituitary adenomas. Frontiers of Hormone Research 32 110-126.
76. Sajjad EA, Zielinski G, Maksymowicz M, Hutnik L, Bednarczuk T & Wlodarski P 2013 mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. Endocrine Pathology 24 11-19. (doi:10.1007/s12022-012-9230-y)
77. Samuels Y & Velculescu VE 2004 Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 1221-1224. (doi:10.4161/cc.3.10.1164)
78. Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S & Asa SL 2012 The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Research 72 5683-5691. (doi:10.1158/0008-5472.CAN-12-2102)
79. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB&Gray JW 1999 PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21 99-102. (doi:10.1038/5042)
80. Sheehan J, Rainey J, Nguyen J, Grimsdale R & Han S 2011 Temozolomide-induced inhibition of pituitary adenoma cells. Journal of Neurosurgery 114 354-358. (doi:10.3171/2010.4.JNS1024)
81. Sherr CJ 2000 The Pezcoller lecture: cancer cell cycles revisited. Cancer Research 60 3689-3695. (Pubitemid 32204552)
82. Sukumari-Ramesh S, Singh N, Dhandapani KM & Vender JR 2011 mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation. Surgical Neurology International 2 22. (doi:10REF76=10.4103/2152-7806.77029)
83. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, Mizukami Y, Okumura T, Testa JR & Kohgo Y 2004 Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Research 64 3486-3490. (doi:10.1158/0008-5472.CAN-03- 1788)
84. Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A & Ezzat S 2011 The FGFR4- G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genetics 7 e1002400. (doi:10.1371/journal.pgen.1002400)
85. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK 2006 Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 66 1576-1582. (doi:10.1158/0008-5472.CAN-05-1189)
86. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG & Melmed S 2008 Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Research 68 6377-6386. (doi:10.1158/0008-5472.CAN-08-0508)
87. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J & Burgering BM 1998 Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation, Characterization of dominant-negative mutant of PKB. Journal of Biological Chemistry 273 13150-13156. (doi:10.1074/jbc.273.21. 13150)
88. Wera S, Belayew A & Martial JA 1995a Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. FEBS Letters 358 158-160. (doi:10.1016/0014-5793(94)01416-X)
89. Wera S, Zheng L, Hooghe-Peters EL, Belayew A, Martial JA & Velkeniers B 1995b Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Endocrine Research 21 623-633.
90. White MF 1998 The IRS-signalling system: a network of docking proteins that mediate insulin action. Molecular and Cellular Biochemistry 182 3-11. (doi:10.1023/A:1006806722619)
91. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H et al. 2004 Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clinical Cancer Research 10 2846-2850. (doi:10.1158/1078-0432.CCR-02-1441)
92. Yoshida Y, Kurokawa T, Horiuchi Y, Sawamura Y, Shinagawa A & Kotsuji F 2010 Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer. European Journal of Cancer 46 3445-3452. (doi:10.1016/j.ejca.2010.09.004)
93. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA & Squire JA 2007 FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British Journal of Cancer 97 678-685. (doi:10.1038/sj.bjc.6603924)
94. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M & Degli Uberti EC 2010 Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 95 968-976. (doi:10.1210/jc.2009-1641)
95. Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen J, Terezakis S, Kleinberg L et al. 2011 Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biology & Therapy 12 657-663. (doi:10.4161/cbt.12.7.17172)
96. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA & Pan D 2003 Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nature Cell Biology 5 578-581. (doi:10.1038/ncb999)